<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067959</url>
  </required_header>
  <id_info>
    <org_study_id>1072-20</org_study_id>
    <nct_id>NCT05067959</nct_id>
  </id_info>
  <brief_title>Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases</brief_title>
  <official_title>Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emek Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 2019-coronavirus disease (COVID-19), caused by SARS-CoV-2, was identified as the source&#xD;
      of pneumonia cases in Wuhan city in China. It rapidly spread worldwide and was declared by&#xD;
      WHO as a pandemic. COVID-19 vaccines are expected to be the breakthrough in controlling the&#xD;
      pandemic. However, studies performed only in healthy adults, and specifically excluded&#xD;
      patients who were under immunomodulatory/biologic therapy, thus excluding patients with&#xD;
      chronic inflammatory diseases (IBD). In this study we wish to understand vaccine efficacy and&#xD;
      immunological response in IBD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall Aims:&#xD;
&#xD;
        1. To assess the immune response to COVID-19 vaccination in patients with IBD.&#xD;
&#xD;
        2. Comparing the short and long term immune response to vaccination among subgroups&#xD;
           receiving different therapies.&#xD;
&#xD;
        3. To evaluate the different variables affecting immunity of these patients.&#xD;
&#xD;
        4. To assess adverse reactions to COVID-19 vaccines and IBD related complications.&#xD;
&#xD;
      Specifically:&#xD;
&#xD;
        1. To assess serologic response to COVID-19 vaccine(s) in patients with IBD treated with&#xD;
           anti-TNF agents (+/- immunomodulators) compared to&#xD;
&#xD;
             1. Healthy controls&#xD;
&#xD;
             2. Patients with IBD not treated with anti-TNF (+/- immunomodulators)&#xD;
&#xD;
        2. To characterize serologic response: seroconversion, seroprotection and persistence of&#xD;
           COVID-19 vaccine(s) in patients with IBD&#xD;
&#xD;
        3. To identify factors associated with serologic response&#xD;
&#xD;
        4. Side effects to vaccines&#xD;
&#xD;
        5. IBD exacerbation compared to activity at baseline&#xD;
&#xD;
        6. Symptomatic COVID-19&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 28, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>vaccine efficacy in IBD population</measure>
    <time_frame>4 weeks post second COVID-19 vaccine.</time_frame>
    <description>â€¢ Efficacy of the vaccination for IBD patients compared to the normal population measured as proportion of patients achieving positive serology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease related variant affect immunological response</measure>
    <time_frame>12 months</time_frame>
    <description>Measuring how the IBD disease activity (remission or flare) affect the response to the vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy related variants affect immunological response</measure>
    <time_frame>12 months</time_frame>
    <description>Measuring how specific IBD therapies and doses, during induction or maintenance, interval between vaccination and anti TNF infusion/injection affect the response to the vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic assessments affect response to vaccine</measure>
    <time_frame>12 months</time_frame>
    <description>Measuring how immunoglobulin levels, lymphocyte subpopulations and HLA phenotype affect the response to the vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events to covid-19 vaccine</measure>
    <time_frame>12 months</time_frame>
    <description>Following Adverse reactions to vaccines</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">284</enrollment>
  <condition>IBD</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>IBD patients</arm_group_label>
    <description>patients with IBD (Chron's disease, Ulcerative colitis, IBD-Unspecify). patients will be divided into two sub-groups: IBD patients on anti-TNF therapy IBD patients on any other therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Covid-19 vaccine</intervention_name>
    <description>blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>IBD patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      complete blood count, CRP, Anti-TNF level and trough from relevant patients, COVID-19&#xD;
      serology including neutralizing antibodies, cytokine levels, lymphocyte subpopulation [CD4&#xD;
      CD8 B CD20/19, NKT], T cell proliferation, immunoglobulin levels.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        IBD patients and healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Adults &gt;18 years of age 2. Patients with either Crohn's disease, ulcerative&#xD;
             colitis, ileostomy, pouch 3. Not vaccinated to COVID-19 [i.e. before 2 mRNA Pfizer&#xD;
             vaccines provided, or before any vaccine provided as one injection 4. Ability to&#xD;
             attend follow up visits 5. Ability to understand and sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>IRIS DOTAN</investigator_full_name>
    <investigator_title>Head of Gasteroenterology Division</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

